Anika Therapeutics, Inc.
ANIK · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $242 | $332 | $431 | $516 |
| - Cash | $56 | $73 | $86 | $94 |
| + Debt | $26 | $29 | $31 | $21 |
| Enterprise Value | $213 | $288 | $376 | $443 |
| Revenue | $120 | $121 | $114 | $148 |
| % Growth | -0.7% | 6.1% | -23% | – |
| Gross Profit | $76 | $83 | $73 | $83 |
| % Margin | 63.4% | 68.3% | 64.3% | 56.1% |
| EBITDA | $3 | $15 | $18 | -$4 |
| % Margin | 2.5% | 12.5% | 16% | -2.8% |
| Net Income | -$56 | -$83 | -$15 | $4 |
| % Margin | -47% | -68.4% | -13.1% | 2.8% |
| EPS Diluted | -3.83 | -5.64 | -1.02 | 0.28 |
| % Growth | 32.1% | -452.9% | -464.3% | – |
| Operating Cash Flow | $5 | -$2 | $4 | $8 |
| Capital Expenditures | -$8 | -$5 | -$7 | -$5 |
| Free Cash Flow | -$2 | -$7 | -$3 | $3 |